EDNRA and pulmonary arterial hypertension: Currently approved drug treatments for PAH focus primarily on reducing pulmonary vascular resistance through the use of prostacyclin analogues, endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase activators.